問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2025-10-18

李岱晃
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李岱晃

List

36Cases

2025-06-16 - 2029-09-30

Active
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study)

  • Condition/Disease

    Bronchiectasis

  • Test Drug

    BI 1291583 or matching placebo

Participate Sites
6Sites

Recruiting6Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting
A phase IIb trial (ARGiNAUT) evaluating the efficacy, safety, and tolerability of AZD8965 in patients with idiopathic pulmonary fibrosis (IPF).

  • Condition/Disease

    Idiopathic pulmonary fibrosis

  • Test Drug

    AZD8965 Film-Coated Tablet

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting1Sites

2026-07-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

  • Condition/Disease

    Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Test Drug

    NS-863

Participate Sites
6Sites

Not yet recruiting1Sites

2025-10-01 - 2028-12-31

Active
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization

  • Condition/Disease

    Bronchiectasis With Pseudomonas Aeruginosa Colonization

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2024-02-26 - 2037-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-12-01 - 2032-01-31

Phase II

Active
SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    ABBV-706

Participate Sites
5Sites

Not yet recruiting1Sites

2025-12-11 - 2031-06-30

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

  • Condition/Disease

    Severe Asthma

  • Test Drug

    GB-0895

Participate Sites
6Sites

Recruiting6Sites

2026-01-29 - 2031-11-15

Phase II/III

Active
AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

  • Condition/Disease

    Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Test Drug

    PF-07275315 Placebo

Participate Sites
7Sites

Recruiting7Sites

2026-02-23 - 2030-03-31

Phase I

Active
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

  • Condition/Disease

    Advanced/Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    輸注液 注射用凍晶粉末 注射用凍晶粉末

Participate Sites
6Sites

Not yet recruiting6Sites

2026-02-26 - 2028-04-30

Phase II

Not yet recruiting
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer (NSCLC)

  • Test Drug

    注射用凍晶粉末

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB